White Papers
AI-ENABLED PHARMACEUTICAL COCRYSTAL SCREENING
This white paper from Lonza and the American Chemical Society explains how AI-enabled cocrystal screening can help pharmaceutical companies identify promising solid forms of APIs earlier.
AI- and Model-Based Tools to Streamline Drug Development
This Lonza resource explains how AI, high-throughput experimentation (HTE), and model-based tools can streamline small-molecule drug development.
Bringing novel ADC formats into the clinic
This white paper from Lonza explains how next-generation antibody-drug conjugates (ADCs), especially antibody-oligonucleotide conjugates (AOCs), are expanding bioconjugate
Advancing ADCs: From concept to commercialization
This Lonza white paper explains how ADC development has evolved and how end-to-end technologies and manufacturing capabilities can help accelerate ADCs from concept to commercialization.
From Discovery to Patients: an Integrated Service for ADC Development by Lonza and Synaffix
This Lonza white paper explains how Synaffix technology and Lonza’s integrated ADC development services can help drug developers move antibody-drug conjugates (ADCs
A Scalable Primary Cell-Based 3D Human Skin Organoid Platform
Advance barrier biology and dermatotoxicology research with a scalable, primary cell-based 3D human skin organoid platform.
Measurement Uncertainty: Improve Confidence in Every Weighing Result
Measurement uncertainty plays a critical role in ensuring reliable laboratory results. Even properly calibrated balances can be affected by environmental conditions, user handling, and other factors that influence weighing accuracy.
The Development–GMP Gap
Why do so many drug development programs lose momentum as they transition from product development into clinical manufacturing?
An Integrated Approach to Quality
How to Tighten the Connection between Quality Management and Document Management
Suitable Alternatives to Fetal Bovine Serum
Alternatives to Fetal Bovine Serum for Routine Cell Culture
